1. Home
  2. TISI vs OKYO Comparison

TISI vs OKYO Comparison

Compare TISI & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Team Inc.

TISI

Team Inc.

HOLD

Current Price

$26.52

Market Cap

101.4M

ML Signal

HOLD

Logo OKYO Pharma Limited

OKYO

OKYO Pharma Limited

HOLD

Current Price

$1.62

Market Cap

87.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TISI
OKYO
Founded
1973
2007
Country
United States
United Kingdom
Employees
6800
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
101.4M
87.6M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
TISI
OKYO
Price
$26.52
$1.62
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$6.33
AVG Volume (30 Days)
26.8K
65.5K
Earning Date
05-12-2026
07-18-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$896,483,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.19
N/A
52 Week Low
$12.34
$1.34
52 Week High
$25.33
$3.20

Technical Indicators

Market Signals
Indicator
TISI
OKYO
Relative Strength Index (RSI) 76.73 53.81
Support Level $13.58 $1.45
Resistance Level N/A $1.73
Average True Range (ATR) 1.21 0.09
MACD 0.21 0.01
Stochastic Oscillator 99.81 60.00

Price Performance

Historical Comparison
TISI
OKYO

About TISI Team Inc.

Team Inc provides specialty industrial services, including inspection, engineering assessment, and mechanical repair and remediation required in maintaining high-temperature and high-pressure piping systems and vessels utilized in refining, petrochemicals, and others. The company operates in two segments, Inspection and Heat Treating and Mechanical Services. The Inspection and Heat Treating segment, which generates maximum revenue, provides conventional and non-destructive testing services for the process, pipeline, and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. Geographically, the company derives its key revenue from the United States, followed by other countries, and Canada.

About OKYO OKYO Pharma Limited

OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.

Share on Social Networks: